New Delhi, May 13 -- Zydus Lifesciences announced on Wednesday that it had signed an agreement via its subsidiary to acquire Assertio Holdings Inc. for $166.4 million in an all-cash deal. Assertio is a Nasdaq-listed pharmaceutical company focused on specialty and oncology supportive-care therapies.

Under the deal, Zydus Worldwide DMCC will acquire all outstanding shares of Assertio for $ 23.50 each, representing total consideration of about $166.4 million on a fully diluted basis.

The acquisition provides Zydus with an established US specialty oncology commercial platform, anchored by Assertio's presence in oncology supportive care, the company said on Wednesday. It plans to leverage Assertio's commercial infrastructure and oncology rel...